Pharmacoepidemiology of the probiotics use in infants
DOI: 10.32364/2618-8430-2020-3-4-309-318
B.M. Blokhin, A.D. Prokhorova, I.P. Lobushkova, A.S. Suyundukova, G.I. Gordiyenko,
V.Yu. Steshin, Z.R. Kagirova, T.Kh. Mirzoev, M.A. Melnikova, N.V. Antipova
Pirogov Russian National Research Medical University, Moscow, Russian Federation
Aim: to obtain clinical data on the use of probiotic drugs in infants with functional gastrointesti-nal disorders (FGIDs).
Patients and Methods: a retrospective cohort study was conducted on the basis of 7 medical in-stitutions in Moscow. Database of 502 case histories of children with diagnosed disorders of in-testinal microbiocenosis was formed. The children were divided into three groups depending on the probiotic agents and other medications for GI: group 1 — medications containing up to two probiotic strains in a composition; group 2 — medications containing more than two probiotic strains in a composition; group 3 — other medications for symptomatic treatment of FGIDs.
Results: 259 case histories of infants were included in the study to analyze the data of the group with FGIDs. The ratio of boys and girls was 50%. In infants on artificial nutrition, the duration of the main symptoms (abdominal pain, flatulence, diarrhea, and changes in stool consistency) was significantly longer (p=0.0002). There was the lowest indicator of the symptoms’ maximum duration in the group of symptomatic treatment for GI without probiotic products. At the same time, the symptoms’ duration in this group differed from multicomponent probiotic medications (p=0.0031), but did not differ from the group of single- and two-component drugs (p=0.15). Adding that, there was a tendency to have differences between single- and two-component drugs and multicomponent ones (p=0.08).
Conclusion: multicomponent probiotic medications do not always have the predominance over the single-component. It is necessary to provide a more rational approach to t he targeted probi-otic therapy prescription with a possible preference for single-component drugs to avoid a num-ber of effects associated with the multicomponent probiotics use, such as antigenic load on the gastrointestinal mucosa, competitive interaction of strains.
Keywords: probiotics, functional gastrointestinal disorders, baby colic, retrospective study.
For citation: Blokhin B.M., Prokhorova A.D., Lobushkova I.P. et al. Pharmacoepidemiology of the probiotics use in infants . Russian Journal of Woman and Child Health. 2020;3(4):309–317. DOI: 10.32364/2618-8430-2020-3-4-309-318.
2. Waikar Y. Infantile Colic: An Overview. J Neonatal Pediatr. 2018;4(1):1–3. DOI: 10.4172/2572-4983.1000153.
3. Григорьев К.И. Функциональные нарушения желудочно-кишечного тракта у детей первых месяцев жизни. Экспериментальная и клиническая гастроэнтерология. 2014;101(1):74–9. [Grigoriev K.I. Functional gastrointestinal tract disorders in children of the first months of life. Eksperimental’naya i klinicheskaya gastroenterologiya. 2014;101(1):74–79 (in Russ.)].
4. Daelemans S., Peeters L., Hauser B., Vandenplas Y. Recent advances in understanding and managing infantile colic. F1000Res. 2018 Sep 7;7: F1000 Faculty Rev-1426. DOI: 10.12688/f1000research.14940.1.
5. Danielsson B., Hwang C.P. Treatment of infantile colic with surface active substance (simethicone). Acta Paediatr Scand. 1985;74(3):446–450. DOI: 10.1111/j.1651-2227.1985.tb11001.x. PMID: 3890465.
6. Metcalf T.J., Irons T.G., Sher L.D., Young P.C. Simethicone in the treatment of infant colic: a randomized, placebo-controlled, multicenter trial. Pediatrics. 1994;94(1):29–34.
7. Anabrees J., Indrio F., Paes B., Al Faleh K. Probiotics for infantile colic: a systematic review. BMC Pediatr. 2013;13:186. DOI: 10.1186/1471-2431-13-186.
8. Szajewska H., Dziechciarz P., Mrukowicz J. Meta-analysis: Smectite in the treatment of acute infectious diarrhoea in children. Aliment Pharmacol Ther. 2006 Jan 15;23(2):217–227. DOI: 10.1111/j.1365-2036.2006.02760.x.
9. Guarino A., Ashkenazi S., Gendrel D. et al. European society for pediatric gastroenterology, hepatology, and nutrition/european society for pediatric infectious diseases evidence-based guidelines for the management of acute gastroenteritis in children in Europe: Update 2014. J Pediatr Gastroenterol Nutr. 2014;59(1):132–152. DOI: 10.1097/MPG.0000000000000375.
10. Savino F., Cresi F., Pautasso S. et al. Intestinal microflora in breastfed colicky and non-colicky infants. Acta Paediatr. 2004 Jun;93(6):825–829.
11. Lehtonen L., Korvenranta H., Eerola E. Intestinal microflora in colicky and noncolicky infants: bacterial cultures and gas-liquid chromatography. J Pediatr Gastroenterol Nutr. 1994;19(3):310–314.
12. Savino F., Cordisco L., Tarasco V. et al. Antagonistic effect of Lactobacillus strains against gas-producing coliforms isolated from colicky infants. BMC Microbiol. 2011;11:157. DOI: 10.1186/1471-2180-11-157.
13. Partty A., Luoto R., Kalliomaki M. et al. Effects of early prebiotic and probiotic supplementation on development of gut microbiota and fussing and crying in preterm infants: a randomized, double-blind, placebo-controlled trial. J Pediatr. 2013;163(5):1272–7.e1–2. DOI: 10.1016/j.jpeds.2013.05.035.
14. Захарова И.Н., Дмитриева Ю.А. Пре- и пробиотики в составе детских молочных смесей. Педиатрия. Приложение к журналу Consilium Medicum. 2011;3:20–24. [Zakharova I.N., Dmitrieva S.A. Pre- and probiotics in children’s milk formula. Pediatriyа. Prilozheniye k zhurnalu Consilium Medicum. 2011;3:20–24 (in Russ.)].
15. Braegger C., Chmielewska A., Decsi T. et al. Supplementation of infant formula with probiotics and/or prebiotics: A systematic review and comment by the ESPGHAN committee on nutrition. J Pediatr Gastroenterol Nutr. 2011;52(2):238–250. DOI: 10.1097/MPG.0b013e3181fb9e80.
16. Vendt N., Grünberg H., Tuure T. et al. Growth during the first 6 months of life in infants using formula enriched with Lactobacillus rhamnosus GG: Double-blind, randomized trial. J Hum Nutr Diet. 2006;19:51–58. DOI: /10.1111/j.1365-277X.2006.00660.x.
17. Bäckhed F., Roswall J., Peng Y. et al. Dynamics and stabilization of the human gut microbiome during the first year of life. Cell Host Microbe. 2015;17(6):852. DOI: 10.1016/j.chom.2015.05.012.
18. Partty A., Kalliomaki M., Endo A. et al. Compositional development of Bifidobacterium and Lactobacillus microbiota is linked with crying and fussing in early infancy. PLoS One. 2012;7(3): e32495. DOI: 10.1371/journal.pone.0032495.
19. Van Baarlen P., Troost F.J., Van Hemert S. et al. Differential NF-κB pathways induction by Lactobacillus plantarum in the duodenum of healthy humans correlating with immune tolerance. Proc Natl Acad Sci USA. 2009;106(7):2371–2376. DOI: 10.1073/pnas.0809919106.
20. Verdu E.F. Probiotics effects on gastrointestinal function: Beyond the gut? Neurogastroenterol Motil. 2009;21(5):477–480. DOI: j.1365-2982.2009.01297.x.
21. Chichlowski M., Rudolph C. Visceral pain and gastrointestinal microbiome. J Neurogastroenterol Motil. 2015;21(2):172–181. DOI: /10.5056/jnm15025.
22. Probiotics: Living medicines in health Maintenance and disease prevention. (Electronic resource). URL: https://www.researchgate.net/publication/286032106_Probiotics_Living_medicines_in_health_Maintenance_and_disease_prevention (дата обращения: 21.07.2020).
23. Ong T.G., Gordon M., Banks S.S. et al. Probiotics to prevent infantile colic. Cochrane Database Syst Rev. 2019;3(3): CD012473. DOI: 10.1002/14651858.CD012473.pub2.
24. Беляева И.А. Пробиотические добавки для коррекции младенческих колик: перспективы использования. Эффективная фармакотерапия. 2015;14:14–18. [Belyaeva I.A. Probiotic supplements for infantile colic correction: prospects of use. Effektivnaya farmakoterapiya. 2015;14:14–18 (in Russ.)].
25. Ouwehand A.C., Invernici M.M., Furlaneto F.A.C., Messora M.R. Effectiveness of Multistrain Versus Single-strain Probiotics: Current Status and Recommendations for the Future. J Clin Gastroenterol. 2018;52 Suppl 1, Proceedings from the 9th Probiotics, Prebiotics and New Foods, Nutraceuticals and Botanicals for Nutrition and Human and Microbiota Health Meeting, held in Rome, Italy from September 10 to 12. 2017:S35–S40. DOI: 10.1097/MCG.0000000000001052.
26. Грачева Н.М., Партии О.С. Метаболические пробиотики: перспективы применения в клинике. Фарматека. 2007;2:39–42. [Gracheva N.M., Partii O.S. Metabolic probiotics: prospects for use in the clinic. Farmateka. 2007;2:39–42 (in Russ.)].
27. Khalighi A., Behdani R., Kouhestani S. Probiotics: A Comprehensive Review of Their Classification, Mode of Action and Role in Human Nutrition. In: Probiotics and Prebiotics in Human Nutrition and Health. InTech; 2016. (Electronic resource). URL: http://www.intechopen.com/books/probiotics-and-prebiotics-in-human-nutrition-and-health/probiotics-a-comprehensive-review-of-their-classification-mode-of-action-and-role-in-human-nutrition (дата обращения: 01.06. 2020).
28. Barbieri F., Montanari C., Gardini F., Tabanelli G. Biogenic Amine Production by Lactic Acid Bacteria: A Review. Foods. 2019;8(1):17. DOI: 10.3390/foods8010017.
29. McFarland L.V. Efficacy of Single-Strain Probiotics Versus Multi-Strain Mixtures: Systematic Review of Strain and Disease Specificity. Dig Dis Sci. 2020;(0123456789). (Electronic resource). URL: https://doi.org/10.1007/s10620–020–06244-z (дата обращения: 06.01.2020).
30. Tintore M., Colome G., Santas J., Espadaler J. Gut Microbiota Dysbiosis and Role of Probiotics in Infant Colic. Arch Clin Microbiol. 2017;08(04):1–7.
This work is licensed under a Creative Commons «Attribution» 4.0 License.
